Seminars in Oncology
Volume 30, Issue 2 , Pages 161-164, April 2003

Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation☆☆

HMDS Laboratory, The General Infirmary at Leeds, Leeds, UK

Abstract 

Indolent lymphoproliferative disorders such as Waldenstrom's macroglobulinemia (WM) are characterized by defective apoptosis, which leads to progressive accumulation of slowly dividing neoplastic lymphocytes. Activation of nuclear factor kappa B (NFκB) is considered to have a central pathogenic role in some hematological malignancies, including multiple myeloma, Hodgkin's disease, and extranodal marginal zone lymphoma (ENMZL). NFκB activation may inhibit apoptosis through the transactivation of genes such as Bcl-2 and may therefore be an important mechanism in indolent lymphoproliferative disorders, including WM. In order to assess this potential mechanism, we used immunohistochemistry to determine the presence and subcellular localisation of the major NFκB subunits p50 and p65. Nuclear staining of NFκB subunits (indicative of activation) was not seen in any of the 40 cases examined. Thirty-seven (95%) cases showed cytoplasmic positivity for both p50 and p65 and one case demonstrated cytoplasmic staining for p65 alone, while the two remaining cases showed complete absence of staining. We would therefore conclude that NFκB activation is not a feature of WM and that alternative mechanisms of apoptosis inhibition should be investigated in this disorder. Semin Oncol 30:161-164. © 2003 Elsevier Inc. All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address reprint requests to Dr Roger G. Owen, HMDS Laboratory, The General Infirmary at Leeds, Great George Street, Leeds, UK LS1 3EX.

☆☆ 0093-7754/03/3002-0014$30.00/0

PII: S0093-7754(03)70069-4

doi:10.1053/sonc.2003.50049

Seminars in Oncology
Volume 30, Issue 2 , Pages 161-164, April 2003